.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Refining Systemic Therapy for Multiple Myeloma

EP. 1: Identifying Between Smoldering and Active Myeloma

January 16th 2019

EP. 2: Treating Newly Diagnosed High-Risk Smoldering Myeloma

January 16th 2019

EP. 3: Up-front Therapy With Carfilzomib in Myeloma

January 16th 2019

EP. 4: Quadruplet Therapy Prior to Transplant in Myeloma

January 16th 2019

EP. 5: Assessing MRD Status in Myeloma

January 16th 2019

EP. 6: Newer Regimens in Myeloma: A Need for Transplant?

January 16th 2019

EP. 7: Role of Consolidation Therapy in Myeloma

January 16th 2019

EP. 8: Role of Maintenance Therapy in Myeloma

January 16th 2019

EP. 9: Tailored Therapy for Elderly/Frail Patients With Myeloma

January 16th 2019

EP. 10: Transplant-Ineligible Myeloma: Daratumumab

January 16th 2019

EP. 11: Preferred Regimens for Relapsed Myeloma

January 16th 2019

EP. 12: Proteasome Inhibitors in Relapsed-Refractory Myeloma

January 16th 2019

EP. 13: Monoclonal Antibodies in Relapsed-Refractory Myeloma

January 16th 2019

EP. 14: Emerging Therapies in Myeloma: Venetoclax

January 16th 2019

EP. 15: Emerging Therapies in Myeloma: Selinexor

January 16th 2019

EP. 16: Antibody-Drug Conjugates in Myeloma

January 16th 2019

EP. 17: CAR T-Cell Therapy in Myeloma

January 16th 2019